Focused On-demand Library for Heterogeneous nuclear ribonucleoprotein H2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P55795

UPID:

HNRH2_HUMAN

Alternative names:

FTP-3; Heterogeneous nuclear ribonucleoprotein H'

Alternative UPACC:

P55795; A1L400; Q9HHA7

Background:

Heterogeneous nuclear ribonucleoprotein H2 (hnRNP H2), also known as FTP-3, plays a crucial role in the processing of pre-mRNAs into functional mRNAs, a fundamental step in gene expression. It binds specifically to poly(RG) sequences, indicating its involvement in the regulation of RNA metabolism.

Therapeutic significance:

The protein is linked to Intellectual developmental disorder, X-linked, syndromic, Bain type, characterized by developmental delay, intellectual disability, and seizures, among other symptoms. Targeting hnRNP H2 could offer new avenues for therapeutic interventions in treating this disorder.